Related Articles
HDAC6‑selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in multiple myeloma
Selective inhibition of HDAC6 sensitizes cutaneous T‑cell lymphoma to PI3K inhibitors
Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer
Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment
Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells